VANCOUVER, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a letter (the “Deficiency Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated February 2, 2023, stating that following the resignation of Dr. Williamson from the Company’s board of directors and audit committee…


Previous articleBullseye Chart: The Psychedelic Drug Development Pipeline
Next articlePT388 – Vital Psychedelic Conversations